U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022

SARS-CoV-2 seroprevalence surveys provide critical information to assess the burden of COVID-19, describe population immunity, and guide public health strategies. Early in the pandemic, most of these surveys were conducted within high-income countries, leaving significant knowledge gaps in low-and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben Hamida, Amen, Charles, Myrna, Murrill, Christopher, Henao, Olga, Gallagher, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490761/
https://www.ncbi.nlm.nih.gov/pubmed/36157894
http://dx.doi.org/10.1371/journal.pgph.0000658
_version_ 1784793152153976832
author Ben Hamida, Amen
Charles, Myrna
Murrill, Christopher
Henao, Olga
Gallagher, Kathleen
author_facet Ben Hamida, Amen
Charles, Myrna
Murrill, Christopher
Henao, Olga
Gallagher, Kathleen
author_sort Ben Hamida, Amen
collection PubMed
description SARS-CoV-2 seroprevalence surveys provide critical information to assess the burden of COVID-19, describe population immunity, and guide public health strategies. Early in the pandemic, most of these surveys were conducted within high-income countries, leaving significant knowledge gaps in low-and middle-income (LMI) countries. To address this gap, the U.S. Centers for Disease Control and Prevention (CDC) is supporting serosurveys internationally. We conducted a descriptive analysis of international serosurveys supported by CDC during May 12, 2020–February 28, 2022, using an internal tracker including data on the type of assistance provided, study design, population surveyed, laboratory testing performed, and status of implementation. Since the beginning of the pandemic, CDC has supported 72 serosurveys (77 serosurvey rounds) in 35 LMI countries by providing technical assistance (TA) on epidemiologic, statistical, and laboratory methods, financial assistance (FA), or both. Among these serosurvey rounds, the majority (61%) received both TA and FA from CDC, 30% received TA only, 3% received only FA, and 5% were part of informal reviews. Fifty-four percent of these serosurveys target the general population, 13% sample pregnant women, 7% sample healthcare workers, 7% sample other special populations (internally displaced persons, patients, students, and people living with HIV), and 18% assess multiple or other populations. These studies are in different stages of implementation, ranging from protocol development to dissemination of results. They are conducted under the leadership of local governments, who have ownership over the data, in collaboration with international partners. Thirty-four surveys rounds have completed data collection. CDC TA and FA of SARS-CoV-2 seroprevalence surveys will enhance the knowledge of the COVID-19 pandemic in almost three dozen LMI countries. Support for these surveys should account for current limitations with interpreting results, focusing efforts on prospective cohorts, identifying, and forecasting disease patterns over time, and helping understand antibody kinetics and correlates of protection.
format Online
Article
Text
id pubmed-9490761
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-94907612023-03-17 U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022 Ben Hamida, Amen Charles, Myrna Murrill, Christopher Henao, Olga Gallagher, Kathleen PLOS Glob Public Health Research Article SARS-CoV-2 seroprevalence surveys provide critical information to assess the burden of COVID-19, describe population immunity, and guide public health strategies. Early in the pandemic, most of these surveys were conducted within high-income countries, leaving significant knowledge gaps in low-and middle-income (LMI) countries. To address this gap, the U.S. Centers for Disease Control and Prevention (CDC) is supporting serosurveys internationally. We conducted a descriptive analysis of international serosurveys supported by CDC during May 12, 2020–February 28, 2022, using an internal tracker including data on the type of assistance provided, study design, population surveyed, laboratory testing performed, and status of implementation. Since the beginning of the pandemic, CDC has supported 72 serosurveys (77 serosurvey rounds) in 35 LMI countries by providing technical assistance (TA) on epidemiologic, statistical, and laboratory methods, financial assistance (FA), or both. Among these serosurvey rounds, the majority (61%) received both TA and FA from CDC, 30% received TA only, 3% received only FA, and 5% were part of informal reviews. Fifty-four percent of these serosurveys target the general population, 13% sample pregnant women, 7% sample healthcare workers, 7% sample other special populations (internally displaced persons, patients, students, and people living with HIV), and 18% assess multiple or other populations. These studies are in different stages of implementation, ranging from protocol development to dissemination of results. They are conducted under the leadership of local governments, who have ownership over the data, in collaboration with international partners. Thirty-four surveys rounds have completed data collection. CDC TA and FA of SARS-CoV-2 seroprevalence surveys will enhance the knowledge of the COVID-19 pandemic in almost three dozen LMI countries. Support for these surveys should account for current limitations with interpreting results, focusing efforts on prospective cohorts, identifying, and forecasting disease patterns over time, and helping understand antibody kinetics and correlates of protection. Public Library of Science 2022-08-05 /pmc/articles/PMC9490761/ /pubmed/36157894 http://dx.doi.org/10.1371/journal.pgph.0000658 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Ben Hamida, Amen
Charles, Myrna
Murrill, Christopher
Henao, Olga
Gallagher, Kathleen
U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022
title U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022
title_full U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022
title_fullStr U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022
title_full_unstemmed U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022
title_short U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022
title_sort u.s. cdc support to international sars-cov-2 seroprevalence surveys, may 2020–february 2022
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490761/
https://www.ncbi.nlm.nih.gov/pubmed/36157894
http://dx.doi.org/10.1371/journal.pgph.0000658
work_keys_str_mv AT benhamidaamen uscdcsupporttointernationalsarscov2seroprevalencesurveysmay2020february2022
AT charlesmyrna uscdcsupporttointernationalsarscov2seroprevalencesurveysmay2020february2022
AT murrillchristopher uscdcsupporttointernationalsarscov2seroprevalencesurveysmay2020february2022
AT henaoolga uscdcsupporttointernationalsarscov2seroprevalencesurveysmay2020february2022
AT gallagherkathleen uscdcsupporttointernationalsarscov2seroprevalencesurveysmay2020february2022